media – Page 12 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

The first domestic product was approved, and stem cell drugs ushered in a historic beginning

On the evening of January 2, the State Food and Drug Administration conditionally approved the listing of Amymetocel injection applied by Bosheng Excellence Biotechnology (Beijing) Co., Ltd. (hereinafter referred to as “Bosheng Excellence”) through the priority review and approval procedure. This is China’s first stem cell therapy drug, used to treat acute graft-versus-host disease with failure of hormone therapy, mainly involving the digestive tract in patients over 14 years old. Graft-versus-host disease is one of the main complications after allogeneic hematopoietic stem cell transplantation, and may cause death in severe cases. Specifically, graft-versus-host disease is a type of multi-organ syndrome that occurs after allogeneic hematopoietic stem cell transplantation when lymphocytes from the donor attack the recipient’s tissues, manifested as tissue inflammation and fibrosis mainly involving the skin, gastrointestinal tract, liver, lungs and mucosal surfaces. Amymetocel injection is a human umbilical cord mesenchymal stem cell injection. Its listing provides a new ...
- Source: drugdu
- 82
- January 7, 2025
The winning bid price of five injections is “less than 1 yuan”, and the price reduction of Chinese medicine centralized procurement exceeds expectations

The results of the third batch of centralized procurement of Chinese patent medicines by the Procurement Alliance for Procurement of Produced Medicines were announced recently, and the price reduction of centralized procurement exceeded market expectations. This round of centralized procurement of Chinese patent medicines involves 20 product groups, and the purchased varieties are mainly Chinese patent medicines that are commonly used in clinical practice, with high purchase amounts and large usage, including oral Chinese patent medicines and Chinese medicine injections. According to the results of the proposed selection announced by the Hubei Medical Security Bureau, a total of 175 products are proposed to be selected, of which 165 are directly proposed to be selected and 10 are supplementary proposed to be selected. The Hubei Medical Security Bureau did not directly announce the average price reduction of the selected varieties, but according to the statistics of different brokerages, the average price ...
- Source: drugdu
- 62
- January 7, 2025
A hospital in Shanxi was accused of having medical staff suspected of participating in the sale of babies, and Datong set up an investigation team

On January 2, it was learned that in response to the online reports that relevant personnel of the First People’s Hospital of Datong City, Shanxi Province were suspected of participating in the sale of babies, Datong City set up a joint investigation team to conduct an investigation. Any violations of laws and disciplines found will be dealt with seriously in accordance with the law and discipline. According to @Fazhi Daily, it is reported that the doctor involved is Wang Mouqing, chief physician of the obstetrics department of the First Hospital of Datong City, Shanxi Province. In 2022, Wang Mouqing received a 15-year-old girl who was about to give birth, but the girl’s family did not want the child. At the same time, another couple who had failed to conceive after two IVF treatments also visited Wang Mouqing. Faced with this situation, Wang Mouqing introduced the two parties. In May of ...
- Source: drugdu
- 57
- January 7, 2025
Africa Health

Organiser：Informa Markets Time：September 2 – 4, 2025 Address：Convention Square 1, Lower Long Street, Cape Town 8001 Exhibition hall：Cape Town International Convention Centre (CTICC) Product range: Medical Devices: Laboratory equipment and configurations, emergency and transportation facilities, surgical equipment, nursing and monitoring equipment, etc. Medical Technologies: Orthopedic and rehabilitation technologies, medical construction facilities and technologies, medical information and communication technologies, etc. Medicines: Various finished drugs, pharmaceuticals, medical excipients, etc. Hospital Consumables: Disposable medical products, medical disinfection products, etc. Medical Items: Medical clothing and laundry technologies, nutritional catering equipment, medical furniture, etc. About Africa Health： Africa Health in Cape Town, South Africa is the most important healthcare event on the African continent. Over the years, the mission and vision of our organization in Africa have been to bridge the gaps among healthcare business, knowledge, and skill development through meaningful connections, bringing the future of healthcare to the African continent and the ...
- Source: drugdu
- 89
- January 7, 2025
【EXPERT Q&A】What are Germany’s measures on drug control?

Drugdu.com expert’s response: Here is the English translation of the detailed summary of Germany’s measures for pharmaceutical regulation: Germany’s Measures for Pharmaceutical Regulation Germany’s measures for pharmaceutical regulation cover multiple aspects to ensure the safety, effectiveness, and accessibility of pharmaceuticals. The following is a detailed summary of Germany’s pharmaceutical regulation measures: Ⅰ. Pharmaceutical Management System Germany implements a joint regulatory system for the production and circulation of pharmaceuticals through federal and state pharmaceutical regulatory authorities. Federal Pharmaceutical Regulatory Authorities: These include the Federal Ministry of Health and Social Security, the Federal Institute for Drugs and Medical Devices (BfArM), the Federal Serum and Vaccine Institute, and the Federal Institute for Consumer Health Protection and Veterinary Medicine. Their main tasks include accepting pharmaceutical registration applications, issuing marketing authorization for pharmaceuticals, testing sera, vaccines, and experimental allergens, compiling pharmacopoeias, and issuing recall directives for pharmaceuticals suspected of having adverse health effects. State Pharmaceutical ...
- Source: drugdu
- 91
- January 6, 2025
Seilong Pharmaceutical’s subsidiary, Famotidine, receives approval for launching

Financial Update, January 1 – Seilong Pharmaceutical (002898) announced that its wholly-owned subsidiary, Hunan Seilong Pharmaceutical Co., Ltd., has recently received the approval notification for the listing application of Famotidine from the National Medical Products Administration. The valid period for this drug is 18 months, and the notification is effective until December 30, 2029, with a registration standard number of YBY77052024. Famotidine is primarily used to treat upper gastrointestinal bleeding caused by peptic ulcers, further enriching the company’s raw material pharmaceutical product pipeline. The company stated that specific production and sales conditions will be influenced by various internal and external environmental changes, which may lead to certain uncertainties. In the first three quarters of 2024, Seilong Pharmaceutical achieved revenue of 219 million yuan, with a net profit attributable to the parent company of -3.69 million yuan. https://finance.eastmoney.com/a/202501013284575136.html
- Source: drugdu
- 59
- January 6, 2025
The first generic version of the new dosage form of the “hematopoietic miracle drug” is released

On December 17, the Class 3 generic drug Eltrombopag ethanolamine dry suspension submitted by Zezheng Pharmaceutical was approved for marketing and deemed to have passed the review, becoming the first generic drug in China . Immune thrombocytopenia (ITP) is a common acquired bleeding disease. Platelets sensitized by platelet-specific autoantibodies are excessively destroyed by the mononuclear macrophage system, autoantibodies inhibit megakaryocytes from producing platelets and cytotoxicity, T cells directly lyse platelets, and antigen-specific T cell immune intolerance cause thrombocytopenia (<100×10^9/L). In clinical practice, glucocorticoids are the first-line drugs commonly used to treat ITP. However, since ITP is a chronic disease that requires long-term medication, the long-term use of glucocorticoids may produce a variety of adverse reactions. Eltrombopag is the world’s first small molecule non-peptide TPO receptor agonist approved for marketing. The drug can interact with the transmembrane domain of the human TPO receptor, initiate a signal cascade reaction, stimulate the proliferation ...
- Source: drugdu
- 51
- January 6, 2025
Yiming Biopharma Completes RMB 200 Million Pre-D Round Financing

Recently, Jiangsu Yiming Biotechnology Co., Ltd. (hereinafter referred to as “Yiming Biotechnology”) announced that it has successfully completed a new round of strategic financing of nearly 200 million yuan. This Pre-D round of financing was funded by Beijing Changping Industrial Development Investment Fund and Beijing Pharmaceutical and Health Industry The joint investment by the investment fund is another round of financing obtained by Yiming Bio after the C+ round of financing in April 2023. Yiming Bio said that as a bridge for ATMPs to go global and commercialize, it has received support from multiple investors in the current complex market environment. This round of financing will be used to further support the construction of Yiming Biopharma’s ATMPs CDMO commercial production base, promote technology iteration, enhance the service capabilities of the CDMO global service network, and consolidate the company’s core competitiveness in the ATMPs drug technology track. , creating a large ...
- Source: drugdu
- 50
- January 6, 2025
$135 million! Liraglutide is coming from China

Recently, Hanyu Pharmaceutical announced that its independently developed GLP-1 Liraglutide Injection has been approved by the FDA for marketing as the first generic version and has officially landed in the United States. As we all know, GLP-1 drugs have become the focus of the market in recent years due to their significant efficacy in reducing blood sugar and weight loss. However, precisely because of the skyrocketing demand, this type of drug has repeatedly faced problems of insufficient production and supply. The launch of Hanyu Pharmaceutical’s liraglutide generics in the U.S. market is not only an important breakthrough for Hanyu Pharmaceuticals in the international market, but also marks the imminent expansion of China’s liraglutide generics. Estimated peak sales of $135 million Liraglutide is a human glucagon-like peptide-1 (GLP-1) analog that can activate human GLP-1 receptors, promote insulin secretion, inhibit glucagon secretion, delay gastric emptying, and increase satiety, thereby reducing blood sugar ...
- Source: drugdu
- 65
- January 6, 2025
21 Health News Daily | The National Healthcare Security Administration will comprehensively promote strict supervision of drug traceability codes; The National Medical Products Administration approves the launch of China’s first stem cell therapy drug

The National Healthcare Security Administration will comprehensively promote strict supervision of drug traceability codes On January 2nd, the National Healthcare Security Administration issued a document clarifying the comprehensive promotion of “code based” strict supervision from January 1st, 2025. It will fully leverage the value of drug traceability code data, build various big data models, expand regulatory application scenarios, and carry out precise crackdowns on illegal and irregular use of medical insurance funds such as swapping and reselling medical insurance drugs, empty brushing and brushing medical insurance cards, and forging prescriptions, and increase the intensity of disposal. The drug traceability code is the only “electronic ID card” for drugs. In April 2024, the National Healthcare Security Administration launched a pilot project for the collection and application of drug traceability codes nationwide. In early November 2024, a public inquiry was conducted on 46 designated pharmaceutical institutions regarding the repeated reimbursement of a ...
- Source: drugdu
- 144
- January 4, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.